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Introduction: Treatment impact on quality of life (QoL) informs 
treatment management decisions in advanced nonsquamous non–
small-cell lung cancer (NS NSCLC). QoL outcomes from the phase 
III PointBreak trial are reported.
Methods: Chemonaive patients (n = 939) with stage IIIB/IV non-
squamous non–small-cell lung cancer and Eastern Cooperative 
Oncology Group performance status 0 to 1 were randomized (1:1) 
to pemetrexed-carboplatin-bevacizumab (pemetrexed arm) or pacli-
taxel-carboplatin-bevacizumab (paclitaxel arm). Patients without 
progressive disease received maintenance pemetrexed-bevacizumab 
(pemetrexed arm) or bevacizumab (paclitaxel arm). QoL was 
assessed using Functional Assessment of Cancer Therapy (FACT)-
General (FACT-G), FACT-Lung (FACT-L), and FACT/Gynecologic 
Oncology Group-Neurotoxicity (FACT-Ntx) instruments. Subscale 
scores, total scores, and trial outcome indices were analyzed using 
linear mixed-effects models. Post hoc analyses examined the associa-
tion between baseline FACT scores and overall survival (OS).
Results: Mean score differences in change from baseline signifi-
cantly favored the pemetrexed arm for the neurotoxicity subscale 
score, FACT-Ntx total scores, and FACT-Ntx trial outcome index. 
They occurred at cycle 2 (p < 0.001) and persisted through induc-
tion cycles 2 to 4 and six maintenance cycles. Investigator-assessed, 
qualitative, drug-related differences in grade 2 (1.6% versus 10.6%) 
and grade 3 (0.0% versus 4.1%) sensory neuropathy and grade 3/4 
fatigue (10.9% versus 5.0%, p = 0.0012) were observed between 
the pemetrexed and paclitaxel arms. Baseline FACT-G, FACT-L, 
and FACT-Ntx scores were significant prognostic factors for OS 
(p < 0.001).
Conclusions: Randomized patients reported similar changes in 
QoL, except for less change from baseline in neurotoxicity on the 
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pemetrexed arm; investigators reported greater neurotoxicity on the 
paclitaxel arm and greater fatigue on the pemetrexed arm. Higher 
baseline FACT scores were favorable prognostic factors for OS.
Key Words: Nonsquamous non–small-cell lung cancer, Pemetrexed, 
Bevacizumab, Functional assessment of cancer therapy, Paclitaxel.
(J Thorac Oncol. 2015;10: 353–359)
Before and throughout the course of treatment, patients with non–small-cell lung cancer (NSCLC) experience 
problematic symptoms associated with their disease, which 
adversely affect their functional status and quality of life 
(QoL).1,2 Many patients with advanced disease do not have 
curative treatment options, and therefore, they seek prolon-
gation of survival without negatively impacting QoL.3 To 
assess patient-reported outcomes, physicians may administer 
questionnaires to patients to measure activities of daily living, 
symptoms, disease-specific or general QoL, or physicians may 
simply ask comparable symptom- or QoL-related questions 
during their clinical assessment of the patient. Interest in these 
patient-reported outcomes has increased as new therapies and 
combination treatments are investigated, many of which have 
similar efficacies; this interest has underscored the impor-
tance of measuring patient-reported outcomes in clinical tri-
als along with traditional end points, such as tumor response 
and survival. As part of this study, we present patients’ reports 
of their experience on treatment by assessment of QoL utiliz-
ing specific, validated patient reported outcome assessments. 
Information gained from patients may add substantial insight 
into the patient experience and may guide decision making for 
the selection of appropriate therapies for a given patient.
In addition to guiding treatment decision making based 
on patient-experienced toxicities, the Functional Assessment 
of Cancer Therapy-Lung (FACT-L) instrument has been used 
previously to predict efficacy outcomes for patients more 
likely to respond to treatment.4 For example, the baseline 
FACT-General (FACT-G) total score (TS) has been shown to 
be a statistically significant predictor of survival in patients 
with advanced lung cancer.5
The phase III PointBreak study, previously reported,6 
compared pemetrexed-carboplatin-bevacizumab followed by 
pemetrexed-bevacizumab (pemetrexed arm) with paclitaxel-
carboplatin-bevacizumab followed by bevacizumab (pacli-
taxel arm) for first-line and maintenance treatment of patients 
with advanced nonsquamous NSCLC. The primary end point 
of superior overall survival (OS) for the pemetrexed arm was 
not met: 12.6 (pemetrexed arm) versus 13.4 months (pacli-
taxel arm); hazard ratio 1.00; p = 0.949.6 The secondary effi-
cacy end point of progression-free survival was superior for 
the pemetrexed arm compared with the paclitaxel arm (6.0 
versus 5.6 months; hazard ratio 0.83; p = 0.012). Both regi-
mens demonstrated tolerability; however, the toxicity profiles 
differed. An additional secondary end point focused on QoL 
and on evaluating differences in patient-reported outcomes, 
as assessed by the FACT-G, FACT-L, and FACT/Gynecologic 
Oncology Group-Neurotoxicity (FACT-Ntx) instruments; 
these results are presented here as are investigator-reported 
toxicity scores and associated resource use. Post hoc analyses 
that examined prognostic factors for OS are also reported.
PATIENTS AND METHODS
Patients
This study included patients with stage IIIB or IV 
advanced nonsquamous NSCLC7 who had no prior systemic 
therapy for lung cancer and an Eastern Cooperative Oncology 
Group performance status (ECOG PS) of 0 or 1; patients with 
stable-treated brain metastases were permitted to participate 
in the study. PointBreak was conducted in accordance with 
the Declaration of Helsinki and Good Clinical Practice guide-
lines, and the protocol was approved by each participating 
center’s ethics review board. All patients provided informed 
consent before receiving treatment for inclusion in the study 
and to comply with the Declaration of Helsinki.6
Treatment
Treatment consisted of up to four cycles of induction 
therapy and for patients with at least stable disease was fol-
lowed by maintenance therapy until disease progression or 
treatment discontinuation. Using the same dosing regimens for 
bevacizumab as in ECOG study E4599,8 eligible patients were 
randomized (1:1 ratio) to either the experimental arm (peme-
trexed arm) or the control arm (paclitaxel arm). The experi-
mental arm included intravenous (IV) pemetrexed (Alimta, 
Eli Lilly and Company, Indianapolis, IN) 500 mg/m2 + carbo-
platin (Paraplatin, Bristol-Myers Squibb, New York, NY) area 
under the curve 6 + bevacizumab (Avastin, Genentech, South 
San Francisco, CA) 15 mg/kg on day 1 of up to four 21-day 
cycles, followed by IV pemetrexed 500 mg/m2 + bevacizumab 
15 mg/kg for maintenance; while the control arm included IV 
paclitaxel (Taxol, Bristol-Myers Squibb) 200 mg/m2 + carbo-
platin area under the curve 6 + bevacizumab 15 mg/kg on day 
1 of up to four 21-day cycles, followed by IV bevacizumab 
15 mg/kg for maintenance. Randomization occurred before 
induction therapy, and patients were stratified according to 
disease stage (IIIB versus IV), ECOG PS (0 versus 1), sex 
(male versus female), and measurable versus nonmeasurable 
disease. Patients randomized to the pemetrexed arm received 
folic acid, vitamin B12 supplementation, and premedication 
per the pemetrexed label9; patients randomized to the pacli-
taxel arm also received premedication per the paclitaxel label.10 
Concomitant supportive therapies, such as erythropoietic 
agents or granulocyte colony-stimulating factors, were allowed 
according to the American Society of Clinical Oncology11 and 
National Comprehensive Cancer Network12 guidelines. After 
four cycles of induction treatment, patients with a complete 
response, partial response, or stable disease, per Response 
Evaluation Criteria in Solid Tumors 1.0,13 received the specified 
maintenance therapy. Patients experiencing protocol-specified 
adverse events had dose reductions or drug discontinuations.1
Toxicity and Patient-Reported 
FACT Assessments
Toxicity analyses included all patients who 
received at least one dose of a study drug. Toxicity was 
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investigator-assessed using the Common Terminology 
Criteria for Adverse Events (CTCAE), version 3.0. Associated 
resource use data were also collected.
Patients independently completed three validated FACT 
instruments: FACT-G, FACT-L, and FACT-Ntx.14–16 Sites 
administered the FACT to patients at each study visit (i.e., 
induction through the end of maintenance therapy) before 
treatment, upon discontinuation, and at the postdiscontinua-
tion follow-up visit. Compliance was defined as the number 
of completed FACT assessments divided by the number of 
expected FACT assessments (i.e., patients still on study at that 
time). Individual subscale scores included the following cat-
egories: a 7-item physical well-being (PWB) subscale score; 
a 7-item social/family well-being (SWB) subscale score; a 
6-item emotional well-being (EWB) subscale score; a 7-item 
functional well-being (FWB) subscale score; a 9-item lung 
cancer subscale (LCS) score; and an 11-item neurotoxicity 
subscale score. Summary scores included FACT-G TS (PWB 
+ SWB + EWB + FWB), FACT-L TS (FACT-G TS + LCS), 
FACT-Ntx TS (FACT-G TS + Ntx), trial outcome index (TOI)-
lung (FACT-L TOI; PWB + FWB + LCS), and FACT-Ntx TOI 
(PWB + FWB + Ntx). Higher scores for each subscale repre-
sented better disease-related or general QoL. The subscales 
were summarized to generate an overall FACT TS or TOI, 
respectively.
Statistical Considerations
Subscale scores, summary TSs, and TOIs were calcu-
lated for each instrument. Treatment arm differences were 
analyzed using linear mixed-effects models, and data collected 
during induction and through the six maintenance cycles were 
included to ensure robust estimates from sufficient numbers 
of patients.
The association between baseline ECOG PS and 
patient-reported FACT scores was explored through logistic 
regression in which ECOG PS (1 versus 0) was the outcome, 
and baseline FACT scores were the exploratory variables. For 
this post hoc analysis, FACT scores were dichotomized based 
on the median.
Additional post hoc analyses explored the effect of 
potential baseline prognostic factors on OS outcomes. Factors 
included treatment, stratification factors (i.e., stage of disease, 
ECOG PS, sex, and measureable disease), baseline FACT 
scores (i.e., FACT-G TS, FACT-L TS, FACT-L TOI, FACT-Ntx 
TS, or FACT-Ntx TOI), and treatment by FACT score interac-
tion. Multivariate Cox-adjusted analyses were used to deter-
mine the relationship between baseline factors and OS.
Toxicity for treatment arms was compared using Fisher’s 
exact test. All tests of treatment effects were conducted at 
a two-sided alpha level of 0.05. Confidence intervals were 
expressed at a two-sided 95% level. The analyses were not 
adjusted to account for multiple comparisons.
RESULTS
Patient and Disease Characteristics
From December 30, 2008, to February 3, 2012, 939 
patients were randomized: 472 to the pemetrexed arm and 
467 to the paclitaxel arm; 885 patients were eligible for safety 
analyses (i.e., 442 pemetrexed arm and 443 paclitaxel arm). 
Overall, 292 patients were eligible for and received mainte-
nance therapy on the pemetrexed arm and 298 were eligible 
for and received maintenance therapy on the paclitaxel arm. 
The demographic and clinical characteristics of patients from 
the intent-to-treat population were balanced1 between the 
pemetrexed arm and the paclitaxel arm: 53.2% and 53.3% 
were males, with a median age of 64.6 and 64.9 years, respec-
tively. The majority of patients, 89.8% (pemetrexed arm) and 
90.1% (paclitaxel arm), had stage IV disease, and 43.9% 
(pemetrexed arm) versus 44.4% (paclitaxel arm) of patients 
had an ECOG PS of 0. Patients with previously treated asymp-
tomatic brain metastases were balanced: 11.0% (pemetrexed 
arm) versus 11.1% (paclitaxel arm).
Prespecified FACT Analyses
Overall compliance, measured by total assessments 
and visits attended (intent-to-treat population), for patients 
completing the FACT instruments was high: 91.2% (peme-
trexed arm) and 90.0% (paclitaxel arm). Baseline mean 
values for FACT subscales, TSs, and TOIs were similar; 
however, for the baseline value, no formal statistical test-
ing occurred between arms (Table 1). For the FACT-G TS, 
FACT-L TS, and FACT-L TOI, no overall significant differ-
ence in mean change from baseline was observed between 
treatment arms (Table 2). No overall differences in mean 
change from baseline were demonstrated for subscale scores, 
except in neurotoxicity (Table 2). Neither treatment arm 
TABLE 1.  Mean Functional Assessment of Cancer Therapy 
Scoresa at Baseline
Pemetrexed  
Arm  
Followed by  
Pemetrexed +  
Bevacizumab  
(n = 472)
Paclitaxel Arm 
Followed by  
Bevacizumab  
(n = 467)
Range of 
Scores
Subscale
  Physical well-being  20.9  20.8 0–28
  Social and family well-being  23.6  23.9 0–28
  Emotional well-being  16.4  16.1 2–24
  Functional well- 
being
 16.1  16.5 0–28
  Lung cancer  18.3  18.3 3–28
  Neurotoxicity  38.2  38.1 10–44
Summary
  FACT-G total  76.9  77.4 24–108
  FACT-L total  95.2  95.5 32–135
  FACT-L TOI  55.3  55.6 16–84
  FACT-Ntx total 115.1 115.4 48–152
  FACT-Ntx TOI  75.2  75.5 21–100
aFACT scores are focused on change from baseline, so no comparison at baseline 
is available. Baseline mean values were similar; however, there is no formal statistical 
testing between arms.
FACT, functional assessment of cancer therapy; G, general; L, lung; Ntx, 
neurotoxicity; paclitaxel arm, paclitaxel + carboplatin + bevacizumab; pemetrexed arm, 
pemetrexed + carboplatin + bevacizumab; TOI, trial outcome index.
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experienced clinically meaningful change (improvement or 
worsening) on the LCS of the FACT-L TOI, as defined by 
Cella et al.17 Patients randomized to the pemetrexed arm had 
significantly less change from baseline at cycle 2 compared 
with patients randomized to the paclitaxel arm (p < 0.001) 
in the neurotoxicity subscale score (−1.26 versus −5.89), the 
FACT-Ntx TS (−0.60 versus −5.48), and the FACT-Ntx TOI 
(−2.79 versus −7.60). These significant differences persisted 
through the three postbaseline (cycle 1 = baseline) induction 
cycles (cycles 2–4) and six cycles of maintenance therapy 
considered in the analysis. For the FACT-Ntx, clinically 
meaningful changes for the neurotoxicity subscale or TOI 
are not well defined in the literature. Based on the FACT 
results, patients randomized to the pemetrexed arm and to 
the paclitaxel arm reported no significant difference in gen-
eral and lung cancer–related QoL (Fig. 1A for lung cancer 
only), whereas patients randomized to the pemetrexed arm 
reported significantly less change from baseline in neuro-
toxicity (p < 0.001) (Fig. 1B).
Investigator-Assessed Toxicity and Resource Use
Fewer patients randomized to the pemetrexed arm expe-
rienced qualitative (not based on a laboratory measurement) 
drug-related grade 2 sensory neuropathy (7 [1.6%] versus 47 
[10.6%]) and grade 3 sensory neuropathy (0 [0.0%] versus 18 
[4.1%]) compared with patients randomized to the paclitaxel 
arm (Table 3); no patients treated on either arm experienced 
drug-related grade 4 or 5 sensory neuropathy. More patients 
treated on the pemetrexed arm versus the paclitaxel arm expe-
rienced the drug-related laboratory toxicities of grade 3/4/5 
anemia (64 [14.5%] versus 12 [2.7%]; p < 0.0001); thrombo-
cytopenia (103 [23.3%] versus 25 [5.6%]; p < 0.0001); and 
the drug-related qualitative toxicity of fatigue (48 [10.9%] 
versus 22 [5.0%]; p = 0.0012). More patients in the paclitaxel 
arm versus the pemetrexed arm experienced drug-related 
grade 3/4/5 neutropenia (180 [40.6%] versus 114 [25.8%]; 
p < 0.0001) and febrile neutropenia (18 [4.1%] versus 6 
[1.4%]; p = 0.0209). Twenty-six percent of patients on the 
pemetrexed arm received at least one transfusion compared 
with 9.9% of patients on the paclitaxel arm. Higher use of 
TABLE 2.  Mean Change from Baseline in Functional 
Assessment of Cancer Therapy Scores
Pemetrexed  
Arm  
followed by  
Pemetrexed +  
Bevacizumab  
(n = 472)
Paclitaxel 
Arm 
followed by  
Bevacizumab 
(n = 467) p Valuea
Subscale
  Physical well-being −1.56 −1.55 0.96
  Social and family well-being 0.09 0.00 0.68
  Emotional well-being 2.00 1.96 0.86
  Functional well-being −0.08 −0.31 0.45
  Lung cancer subscale 1.30 1.42 0.59
  Neurotoxicity subscale −1.26 −5.89 <0.001
Summary
  FACT-G total 0.51 0.18 0.67
  FACT-L total 1.88 1.66 0.82
  FACT-L TOI −0.38 −0.40 0.98
  FACT-Ntx total −0.60 −5.48 <0.001
  FACT-Ntx TOI −2.79 −7.60 <0.001
ap value for treatment is based on a repeat measure analysis with treatment, baseline, 
time point, and treatment by time point interaction as fixed effects.
FACT, functional assessment of cancer therapy; G, general; L, lung; Ntx, 
neurotoxicity; paclitaxel arm, paclitaxel + carboplatin + bevacizumab; pemetrexed arm, 
pemetrexed + carboplatin + bevacizumab; TOI, trial outcome index.
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FIGURE 1.  A, Linear mixed model: mean change from base-
line for the lung cancer subscale. Solid dots, mean change 
from baseline; vertical bars, 95% confidence interval at each 
visit; i1, first induction visit after baseline; m1, first mainte-
nance visit; change = 0. Pac Arm, paclitaxel + carboplatin + 
bevacizumab; Pem Arm, pemetrexed + carboplatin + bevaci-
zumab. B, Linear mixed model: mean change from baseline 
for the neurotoxicity subscale. Solid dots, mean change from  
baseline; vertical bars, 95% confidence interval at each visit;  
i1, first induction visit after baseline; m1, first maintenance 
visit;  change = 0; Pac Arm, paclitaxel + carboplatin + bevaci-
zumab; Pem Arm, pemetrexed + carboplatin + bevacizumab.
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erythropoetic stimulating agents was reported in the peme-
trexed arm (16.9%) compared with the paclitaxel arm (9.0%), 
whereas use of granulocyte colony-stimulating factors was 
lower among patients in the pemetrexed arm (14.8%) com-
pared with the paclitaxel arm (23.8%).
Post Hoc FACT Analyses
For each respective FACT score, patients with baseline 
scores higher than or equal to the median (i.e., better QoL) were 
more likely to have an ECOG status of 0 at baseline compared 
with those with baseline scores lower than the median (Table 4). 
Correlations between baseline FACT scores and ECOG PS for 
the lung cancer and neurotoxicity subscale scores, TSs, and 
TOIs were all highly significant (p < 0.0001).
Results from post hoc, Cox-adjusted analyses of 
prognostic factors for OS in this study population dem-
onstrated that baseline FACT scores higher than or equal 
to the median, disease stage IIIB, female sex, and a base-
line ECOG PS of 0 are independent, significant factors for 
improved survival (Table 5). Initially, multivariate Cox-
adjusted models with additional factors were considered 
and included treatment, interaction between treatment and 
FACT score, and measureable disease as additional covari-
ates. However, these covariates were not significant prog-
nostic factors for survival (data not shown), and thus they 
were removed from the models for simplicity of reporting 
and interpretation.
DISCUSSION
The QoL data, as measured with patient-reported 
instruments such as the FACT, provide insight into the patient 
experience while on treatment and allow the clinician to better 
understand the effects of a drug on the patient, including tox-
icities. These PointBreak results provide insight into the pos-
sible differential effect of pemetrexed-bevacizumab-related 
and paclitaxel-bevacizumab-related toxicities experienced 
by patients.
The FACT-G instrument assesses PWB, SWB, EWB, 
and FWB; however, the PWB portion of the instrument does 
not specifically assess neurotoxicity. The FACT-L includes 
the same factors as the FACT-G, with the addition of lung 
cancer–specific symptoms. Toxicities, such as neurotoxic-
ity, may be difficult for physicians to assess in patients with 
NSCLC. Because neurotoxicity is not represented in either 
TABLE 3.  Investigator-Assigned CTCAEa Possibly Related to a Study Drug (Safety Population)
Pemetrexed  
Arm followed by 
Pemetrexed + 
Bevacizumab  
(n = 442), %
Paclitaxel Arm 
followed by  
Bevacizumab  
(n = 443), %
Pemetrexed Arm 
followed by  
Pemetrexed+  
Bevacizumab  
(n = 442), %
Paclitaxel Arm 
followed by  
Bevacizumab  
(n = 443), %
Pemetrexed Arm 
followed by  
Pemetrexed+  
Bevacizumab  
(n = 442), %
Paclitaxel Arm 
followed by  
Bevacizumab  
(n = 443), %
Grade 2 Grade 2 Grade 3 Grade 3 Grade 4 Grade 4
Anemiab 19.5 12.2 13.3  2.3 1.1  0.5
Thrombocytopeniab  8.6  4.7 13.8  4.3 9.5  1.4
Neutropeniab 10.0  5.2 17.0 14.9 8.8 25.7
Febrile neutropeniab  0.0  0.0  0.9  3.2 0.5  0.9
Fatigueb 18.8 17.6 10.0  5.0 0.9  0.0
Hemorrhage GI/ 
pulmonary
 0.7  0.5  1.4  0.5 0.5  0.0
Thromboembolic event  0.5  0.2  1.6  0.9 1.6  1.1
Neuropathy/sensoryb  1.6 10.6  0.0  4.1 0.0  0.0
Grade 5 events (% 
pemetrexed arm/ 
paclitaxel arm)
Includes: CNS ischemia (0.2/0.7); Cardiac events (0.2/0.7); ARDS (0.5/0.0); infection (0.2/0.0); hemorrhage GI/pulmonary 
(0.5/0.7); Other hemorrhage (0.2/0.2)
Investigator-assessed toxicities reported in the body of the manuscript for grade 3/4/5 have been rounded differently than the data reported and summed for individual grades in 
this table.
aVersion 3.
bSignificant difference between arms for grade 3/4 and grade 3/4/5 toxicities.
ARDS, adult respiratory distress syndrome; CNS, central nervous system; CTCAE, Common Terminology Criteria for Adverse Events; GI, gastrointestinal; paclitaxel arm, 
paclitaxel + carboplatin + bevacizumab; pemetrexed arm, pemetrexed + carboplatin + bevacizumab.
TABLE 4.  Post Hoc Analyses: Association of Functional 
Assessment of Cancer Therapy Scores with ECOG PS (1 vs. 0) 
at Baseline
FACT Component n Odds Ratio p Value
Lung cancer subscale (median = 19)a 886 0.36 <0.0001
Neurotoxicity subscale (median = 40)a 877 0.40 <0.0001
FACT-G total (median = 78)a 884 0.39 <0.0001
FACT-L total (median = 96.5)a 882 0.31 <0.0001
FACT-L TOI (median = 56)a 883 0.25 <0.0001
FACT-Ntx total (median = 117)a 874 0.33 <0.0001
FACT-Ntx TOI (median = 77)a 875 0.27 <0.0001
aThe reference category for analysis of each FACT component was “score lower than 
the median.” Patients with a baseline FACT score higher or equal to the median are less 
likely to have an ECOG PS of 1.
ECOG PS, Eastern Cooperative Oncology Group performance status; FACT, 
functional assessment of cancer therapy; G, general; L, lung; Ntx, neurotoxicity; TOI, 
trial outcome index.
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the FACT-L or FACT-G scores, the FACT-Ntx instrument 
was used. Results from the FACT-G, FACT-L, and FACT-
Ntx instruments report unique insight from the patient per-
spective on QoL while they are receiving these respective 
drug therapies. In PointBreak, patients on the two respective 
treatment arms did not report differences in general QoL 
or lung cancer–related QoL via the FACT-G and FACT-L, 
respectively. Importantly, the LCS of the FACT-L did not dif-
fer between treatment arms, whereas the neurotoxicity sub-
scale of the FACT-Ntx did differ between arms. Less change 
from baseline in neurotoxicity was reported by patients via 
the neurotoxicity subscale and FACT-Ntx summary scores 
on the pemetrexed arm, which indicates that patients who 
received pemetrexed-bevacizumab experienced better 
QoL specific to their experience with neurotoxicity com-
pared with patients who received paclitaxel-bevacizumab. 
Interestingly, patient-reported neurotoxicity was consistent 
with the clinically measured, qualitative, drug-related, grade 
2/3 sensory neuropathy reported by physicians, suggesting 
that physicians do not have difficulty assessing neurotoxici-
ties by CTCAE in patients with NSCLC. Here, the FACT-
Ntx did not provide additional insight into the treatment 
decision. Nonetheless, in instances where patient symptoms 
are not well defined, the clinical assessment may not coin-
cide with the patient assessment for an individual patient. 
Morton et al.18 reported that peripheral neuropathy may be 
underreported when assessed with CTCAE compared with 
a patient-reported measurement. Thus, seeking direct patient 
input on specific qualitative toxicities may more comprehen-
sively inform a clinician’s assessment of patient-experienced 
toxicity. Because instrument completion may be rare outside 
of the clinical trial setting, physicians should discuss non-
laboratory, qualitative toxicities, such as neurotoxicity and 
fatigue, with patients to understand the effect of specific tox-
icities on their QoL.
In this study, investigator-assessed grade 3/4 fatigue 
(p = 0.0012), and grade 3/4/5 anemia (p < 0.0001), was statis-
tically higher in the pemetrexed arm. Both fatigue and anemia 
have been reported with pemetrexed,19–21 and anemia has been 
reported to contribute to fatigue.22 How fatigue impacted the 
patients’ QoL was not well assessed from the patient perspec-
tive. Although the FACT-L does not directly assess patient 
fatigue, the instrument does contain the PWB subscale, which 
includes an item about patient lack of energy among other 
physical effects. However, this single item is not individually 
validated and thus should not be used as a measure of fatigue. 
Nonetheless, the mean change from baseline was not statis-
tically different for patient-reported PWB between the two 
treatment arms of this study. This suggests that when all toxic-
ities assessed by PWB are combined, the higher level of inves-
tigator-reported fatigue in the pemetrexed arm did not result 
in a differential impact on patient-reported physical QoL. In 
addition, prespecified end points and analyses are required to 
further validate the exploratory findings of the prognostic fac-
tors analysis presented here.
Higher baseline FACT-G, FACT-L, and FACT-Ntx 
scores were found to be favorable prognostic factors for OS 
in these advanced nonsquamous NSCLC patients. Although 
baseline FACT scores and ECOG PS were significantly cor-
related, the FACT scores were independently prognostic in 
the multivariate analyses; thus, the patient-reported FACT 
data provide additional prognostic relevance when assessing 
a patient upon diagnosis. Patient-reported data capture infor-
mation beyond the traditional ECOG PS assessment. Among 
other known prognostic factors for NSCLC, baseline QoL is 
an important consideration for treatment selection and other 
clinical decisions when treating a patient. A previous study 
has shown prognostic ability of the FACT-G in small-cell lung 
cancer patients.23
Results from this trial should not be generalized to popu-
lations beyond this study cohort of advanced nonsquamous 
NSCLC patients and these study drugs. Patients included in this 
study had an ECOG PS of either 0 or 1; therefore, results from 
this study may not apply to patients with poorer ECOG PS.
TABLE 5.  Prognostic Factorsa for Overall Survival: Results 
from Cox-Adjusted, Post Hoc Analyses
Hazard Ratio  
(95% CI) p Value
FACT-G total model
  FACT-G (median = 78; score ≥78 vs. 
score <78)
0.66 (0.56–0.77) <0.001
  Disease stage (stage IIIB vs. stage IV) 0.68 (0.52–0.89)  0.006
  Sex (female vs. male) 0.79 (0.68–0.93)  0.004
  ECOG (PS 1 vs. PS 0) 1.38 (1.17–1.62) <0.001
FACT-L total model
  FACT-L (median = 96.5; score ≥96.5 vs. 
score <96.5)
0.63 (0.53–0.74) <0.001
  Disease stage (stage IIIB vs. stage IV) 0.70 (0.53–0.93)  0.012
  Sex (female vs. male) 0.80 (0.69–0.94)  0.007
  ECOG (PS 1 vs. PS 0) 1.34 (1.13–1.58) <0.001
FACT-L TOI model
  FACT-L TOI (median = 56; score ≥56 
vs. score <56)
0.58 (0.49–0.69) <0.001
  Disease stage (stage IIIB vs. stage IV) 0.67 (0.51–0.89)  0.006
  Sex (female vs. male) 0.81 (0.70–0.95)  0.011
  ECOG (PS 1 vs. PS 0) 1.27 (1.08–1.51)  0.005
FACT-Ntx total model
  FACT-Ntx (median = 117; score ≥117 
vs. score <117)
0.64 (0.55–0.76) <0.001
  Disease stage (stage IIIB vs. stage IV) 0.68 (0.52–0.90)  0.008
  Sex (female vs. male) 0.80 (0.68–0.93)  0.005
  ECOG (PS 1 vs. PS 0) 1.36 (1.16–1.61) <0.001
FACT-Ntx TOI model
  FACT-Ntx TOI (median = 77; score ≥77 
vs. score <77)
0.60 (0.51–0.70) <0.001
  Disease stage (stage IIIB vs. stage IV) 0.69 (0.52–0.91)  0.010
  Sex (female vs. male) 0.81 (0.69–0.95)  0.010
  ECOG (PS 1 vs. PS 0) 1.31 (1.11–1.54)  0.002
aTreatment, treatment by FACT score interaction, and measurable disease were 
included in models, but results were not significant and therefore were not included to 
simplify the table.
CI, confidence interval; ECOG, Eastern Cooperative Oncology Group; FACT, 
functional assessment of cancer therapy; G, general; L, lung; Ntx, neurotoxicity; PS, 
performance status; TOI, trial outcome index.
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CONCLUSIONS
In conclusion, patients treated with pemetrexed and 
paclitaxel reported similar changes in general QoL and lung 
cancer–related QoL, whereas neurotoxicity-related changes 
by both patient- and investigator-reported outcomes differed 
significantly and were worse in the paclitaxel arm. These 
data suggest that nonsquamous NSCLC patients, particularly 
those more susceptible to neurotoxicity due to comorbidities 
(e.g., older age or diabetes), may experience less neurotoxic-
ity if treated with the pemetrexed arm regimen.24–27 Although 
no specific patient-reported outcome data were collected for 
fatigue, the investigator-reported outcome data suggest that 
the potential toxicity of fatigue should also be considered 
when making a treatment decision.
Baseline FACT scores higher than or equal to the 
median, in addition to known and previously reported lower 
stage of disease, female sex, and lower baseline ECOG PS, 
have been shown to be prognostic for OS, which suggests that 
QoL assessment may be used to inform treatment decisions 
regarding who to treat and with which therapy. The addition of 
baseline QoL data may be particularly useful for patients with 
a borderline treatment status to help the clinician make a deci-
sion regarding more versus less aggressive therapy.
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